Indacaterol plus tiotropium versus tiotropium alone in moderate to severe COPD

Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Indacaterol + tiotropium with Tiotropium alone (2 arms). Primary endpoint: Standardized AUC for FEV1 from 5 minutes to 8 hours post-dose at week 12. Started Jan 2009; status: completed.